Archford Capital Strategies’s Biogen BIIB Stock Holding History

Archford Capital Strategies’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-50	Closed	-$12K	–	250
2019 Q2	$12K	Hold	50	–	–	﹤0.01%	389
2019 Q1	$12K	Hold	50	–	–	﹤0.01%	375
2018 Q4	$15K	Hold	50	–	–	0.01%	344
2018 Q3	$18K	Hold	50	–	–	0.01%	372
2018 Q2	$15K	Hold	50	–	–	0.01%	392
2018 Q1	$16K	Buy	+50	New	+$15.5K	0.01%	299
2017 Q2	–	Sell	-50	Closed	-$14K	–	245
2017 Q1	$14K	Sell	50 -4	-7%	-$1.13K	0.01%	401
2016 Q4	$15K	Hold	54	–	–	0.01%	343
2016 Q3	$16K	Sell	54 -20	-27%	-$5.92K	0.01%	339
2016 Q2	$18K	Buy	+74	New	+$19.5K	0.01%	339
2016 Q1	–	Sell	-74	Closed	-$23K	–	225
2015 Q4	$23K	Buy	74 +4	+6%	+$1.15K	0.01%	355
2015 Q3	$21K	Buy	70 +14	+25%	+$4.62K	0.02%	269
2015 Q2	$22K	Buy	56 +54	+2,700%	+$21.7K	0.02%	268
2015 Q1	$844	Buy	+2	New	+$788	﹤0.01%	651

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Archford Capital Strategies's BIIB Position: Q3 2019 in Review

Archford Capital Strategies sold out of Biogen (BIIB) in Q3 2019, closing a stake of 50 shares — an estimated $12K sold.

Archford Capital Strategies first reported a position in BIIB in Q1 2015 and held it in 14 quarters. The position peaked at $23K in Q4 2015. 988 funds tracked by Wall St. Rank hold BIIB as of Q3 2019.

Archford Capital Strategies reported no remaining Biogen position as of Q3 2019 after selling out during the quarter.
Archford Capital Strategies sold 50 Biogen shares in Q3 2019, an estimated $12K.
Archford Capital Strategies first reported a position in Biogen in Q1 2015 and held it in 14 quarters.
Archford Capital Strategies's Biogen position peaked at $23K in Q4 2015.
988 funds tracked by Wall St. Rank held Biogen as of Q3 2019.

Based on Archford Capital Strategies's 13F filing for Q3 2019, filed 23 Oct 2019.